Welcome to our dedicated page for Iveric Bio news (Ticker: ISEE), a resource for investors and traders seeking the latest updates and insights on Iveric Bio stock.
Iveric Bio (NASDAQ: ISEE), now a subsidiary of Astellas Pharma, remains a leader in developing innovative therapies for retinal diseases including age-related macular degeneration. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic developments following the company's acquisition.
Access timely updates on Avacincaptad Pegol and other pipeline candidates targeting Geographic Atrophy. Our curated news collection features official press releases, trial result analyses, and partnership announcements from trusted sources. Track progress in ophthalmology research through verified updates on therapeutic advancements and regulatory pathways.
Key content includes updates on late-stage clinical programs, manufacturing developments, and scientific collaborations. All information is vetted for accuracy and relevance to investor decision-making. Bookmark this page for streamlined access to critical updates about Iveric Bio's contributions to retinal disease treatment under Astellas' global infrastructure.
Iveric bio, Inc. (ISEE) has announced significant findings from the GATHER clinical trials regarding avacincaptad pegol (ACP) for treating geographic atrophy (GA) linked to age-related macular degeneration. The post-hoc analysis indicated a 56% reduction in persistent vision loss in patients receiving ACP compared to sham treatments over 12 months. Notably, this analysis established a connection between decreased GA growth and lower rates of vision loss for the first time. The company aims to demonstrate the efficacy and safety of ACP as it seeks FDA approval. These results were presented at the 2023 ARVO annual meeting, highlighting ACP's potential to address a critical unmet need in retinal disease treatment.
Iveric Bio, Inc. (NASDAQ: ISEE) announced on April 3, 2023, the grant of equity-based awards to nine new non-executive employees. These inducement grants were made under the Company’s 2019 Inducement Stock Incentive Plan and consist of non-statutory stock options for 166,000 shares and 27,000 restricted stock units. The stock options have an exercise price of $26.49 per share and a vesting schedule spanning four years, with 25% vesting on April 3, 2024. Iveric Bio focuses on developing treatments for retinal diseases and aims to improve patient outcomes in this area.
Iveric Bio (NASDAQ: ISEE) announced on
IVERIC bio, Inc. (ISEE) announced the FDA's acceptance of its New Drug Application (NDA) for avacincaptad pegol (ACP) for treating geographic atrophy (GA) associated with age-related macular degeneration (AMD), granting priority review with a PDUFA date of August 19, 2023. A post-hoc analysis from GATHER trials indicated up to a 59% reduction in vision loss at 12 months. The company's commercial launch preparations are accelerating, with a full U.S. sales team expected by April. Financially, IVERIC reported a net loss of $185.2 million for 2022, with R&D expenses increasing to $117.0 million as the company progresses in developing treatments for retinal diseases.
Iveric Bio (Nasdaq: ISEE) announced significant results from a post-hoc time-to-event analysis of its GATHER clinical trials, demonstrating up to a 59% reduction in the rate of vision loss at 12 months when treated with avacincaptad pegol (ACP) 2 mg compared to sham treatment. The GATHER1 and GATHER2 trials focused on patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This analysis, to be presented at the ARVO Annual Meeting from April 23-27, 2023, indicates a strong clinical relevance and supports the efficacy of ACP 2 mg. Iveric Bio continues to investigate ACP under FDA evaluation, targeting a critical unmet need in retinal diseases.
